ZyGEM Corporation Strengthens U.S. Presence and Closes First Round of New Financing

ZyGEM Corporation Strengthens U.S. Presence and Closes First Round of New Financing

SOLANA BEACH, Calif. and HAMILTON, New Zealand, Jan. 7 -- ZyGEM Corp. Ltd., a leading developer and manufacturer of unique enzymatic solutions for DNA extraction and detection and other life sciences applications, today announced the opening of its U.S. headquarters in Solana Beach, California. Under the direction of recently appointed ZyGEM president and CEO Paul Kinnon, the U.S. organization will focus on expanding the company's life sciences product portfolio and geographic reach, leveraging ZyGEM's proprietary culture collection and expertise in enzymes isolated from extreme environments. Separately, the company also announced that it has closed the first round of a financing from existing private venture investors.

"Establishing our new U.S. business headquarters is a major step in ZyGEM's global expansion, building on the strong foundation provided by our New Zealand R&D and headquarters facility," said Mr. Kinnon. "We also are moving rapidly to broaden the life sciences applications of our innovative enzyme technology, as well as expanding geographically in North America, Europe and Asia. The infusion of funds from existing investors in this first closing of our ongoing financing is helping to fuel these ambitious efforts, as well as the expansion of our R&D efforts into the clinical sector."

ZyGEM develops and markets innovative enzyme-based products for life sciences research and related applications. ZyGEM's current products use unique enzymes that have been isolated from the company's proprietary culture collection to provide creative DNA extraction and detection solutions for a variety of markets, including forensics, livestock and agriculture, basic research and clinical applications. ZyGEM's technology and product portfolio are based on more than two decades of research and development on the company's exclusive collection of microorganisms and fungi isolated from extreme environments.

Current ZyGEM products encompass a variety of enzyme-based reagents, including DNA extraction and detection formulations specifically tailored to the needs of specialty markets such as forensics and high throughput livestock genetics analysis. Using a unique single closed tube system that is easily automated with standard robotics, these products provide significant benefits over existing approaches, including reduced risk of sample contamination or staff infection, substantial cost savings, much faster process times, increased accuracy and greater yields from small samples.

ZyGEM's new U.S. headquarters is located in at 462 Stevens Avenue, Suite 304, Solana Beach, CA 92075, telephone: (858) 720-8333. Solana Beach is located in San Diego County, about 30 minutes north of the City of San Diego.

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company's exclusive collection of microorganisms from extreme environments. ZyGEM's technology has significant competitive advantages over existing methods and has potential applications in multiple market sectors. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S. For more information, visit http://www.ZyGEM.com

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.